## 3 Results
\begin{table}
\begin{tabular}{l l l l} \hline \hline
**Variables** & \begin{tabular}{l} **Group N** \\ **(n = 39)** \\ \end{tabular} & \
\begin{tabular}{l} **Group C** \\ **(n = 39)** \\ \end{tabular} &
\begin{tabular}{l} **\(p\)=** \\ \end{tabular} \\ \hline Age (mean \(\pm\) SD) & 38.69 \(\pm\) 10.89 & 43.13 \(\pm\) 12.07 & 0.092 \\ \hline Gender & 16 \(\sigma\) (41.0\%) & 22 \(\sigma\) (56.4\%) & 0.174 \\ \hline ESS & 14.05 \(\pm\) 4.80 & 8.09 \(\pm\) 5.27 & 0.001 \({}^{*}\) \\ \hline PSQI & 7.68 \(\pm\) 2.57 & 6.75 \(\pm\) 4.19 & 0.267 \\ \hline TMD pain screener over cut-off & 10.2\% (n = 4) & 28.2\% (n = 11) & 0.021 \({}^{*}\) \\ \hline TIB (min) & 484.99 \(\pm\) 66.89 & 506.79 \(\pm\) 66.47 & 0.377 \\ \hline LS (min) & 5.15 \(\pm\) 7.59 & 20.14 \(\pm\) 19.27 & 0.001 \({}^{*}\) \\ \hline LR (min) & 27.13 \(\pm\) 37.88 & 81.90 \(\pm\) 14.68 & 0.001 \({}^{*}\) \\ \hline TST (min) & 413.21 \(\pm\) 53.21 & 396.35 \(\pm\) 63.58 & 0.406 \\ \hline WASO (min) & 66.63 \(\pm\) 47.20 & 90.30 \(\pm\) 77.88 & 0.254 \\ \hline \%ST N1 & 9.91 \(\pm\) 6.78 & 3.23 \(\pm\) 1.57 & 0.004 \({}^{*}\) \\ \hline \%ST N2 & 39.28 \(\pm\) 8.07 & 42.56 \(\pm\) 9.70 & 0.297 \\ \hline \%ST N3 & 29.46 \(\pm\) 12.54 & 29.88 \(\pm\) 10.51 & 0.926 \\ \hline \%ST REM & 21.35 \(\pm\) 5.62 & 24.33 \(\pm\) 3.05 & 0.120 \\ \hline AHI & 2.21 \(\pm\) 3.22 & 0.96 \(\pm\) 1.76 & 0.256 \\ \hline \hline \end{tabular} \(p\) values marked with * show a statistically significant difference between groups. ESS = Epworth Sleepiness Scale; PSQI = Pittsburgh Sleep Quality Index, TMD = temporomandibularbular disorder; TIB = time in bed; LS = sleep latency; LR = REM latency; TST = total sleep time; WASO = wakefulness after sleep onset; REM = rapid eye movement; AHI = apnea hypopnea index.  
\end{table} 
Table 1: Sample description, sleep architecture, and AHI. \begin{table}
\begin{tabular}{l l l l l} \hline \hline
**Muscles** & \begin{tabular}{l} **Group N** **(n = 39)** \\ \end{tabular} & \begin{tabular}{l} **Group C** **(n = 39)** \\ \end{tabular} & \
\begin{tabular}{l} **t=** \\ \end{tabular} &
\begin{tabular}{l} **\(p\)=** \\ \end{tabular} \\ \hline Anterior Temporal & 2.53 \(\pm\) 0.80 & 2.43 \(\pm\) 0.76 & \(-\)0.753 & 0.442 \\ \hline Middle Temporal & 2.97 \(\pm\) 1.04 & 2.89 \(\pm\) 1.00 & \(-\)0.437 & 0.634 \\ \hline Posterior Temporal & 3.35 \(\pm\) 1.07 & 3.24 \(\pm\) 0.99 & \(-\)0.360 & 0.500 \\ \hline Masseter & 2.07 \(\pm\) 0.71 & 1.98 \(\pm\) 0.63 & 0.571 & 0.392 \\ \hline Sternocleidomastoid & 1.60 \(\pm\) 0.59 & 1.58 \(\pm\) 0.51 & \(-\)1.150 & 0.788 \\ \hline Occipital & 2.95 \(\pm\) 1.23 & 2.96 \(\pm\) 1.22 & 0.364 & 0.948 \\ \hline Splenius capitis & 2.73 \(\pm\) 1.02 & 2.18 \(\pm\) 0.75 & \(-\)1.831 & 0.238 \\ \hline Thenar & 4.65 \(\pm\) 1.73 & 4.51 \(\pm\) 1.67 & 0.403 & 0.606 \\ \hline \hline \end{tabular} \(\text{PPT}\) = Pressure Pain Threshold.  
\end{table} 
Table 2: Mean PPT and standard deviation (SD) recorded in the two groups (kg/cm\({}^{2}\)) and comparisons between the groups (\(t\) test). \begin{table}
\begin{tabular}{l l l l} \hline \hline  & \begin{tabular}{l} **Group N** **(n = 39)** \\ \end{tabular} & \begin{tabular}{l} **Group C** ** **(n = 39)** \\ \end{tabular} & \
\begin{tabular}{l} **\(X^{2}\)=** \\ \end{tabular} &
\begin{tabular}{l} **\(p\)=** \\ \end{tabular} \\ \hline TMD & 28.2\% (n = 11) & 38.5\% (n = 15) & 0.923 & 0.337 \\ \hline Muscle TMD & 20.5\% (n = 8) & 23.1\% (n = 9) & 0.075 & 0.784 \\ \hline Articular TMD & 23.1\% (n = 9) & 28.2\% (n = 11) & 0.269 & 0.604 \\ \hline Reported Headache & 38.5\% (n = 15) & 30.8\% (n = 12) & 0.510 & 0.475 \\ \hline Pain on muscle palpation & 33.3\% (n = 13) & 33.3\% (n = 13) & 0.000 & 1.000 \\ \hline \hline \end{tabular}  
\(\text{TMD}\) = temporomandibularbular disorders.  
\end{table} 
Table 3: Comparison of prevalence of TMD diagnoses between the two groups (X\({}^{2}\) test). Prevalence is reported as percentage and number of subjects.